Page 1,604«..1020..1,6031,6041,6051,606..1,6101,620..»

Is Medtronic’s Artificial Pancreas the Next Big Thing in Diabetes? – Motley Fool

Posted: April 13, 2017 at 7:40 pm

Last fall, Medtronic (NYSE:MDT) won FDA approval of a closed-loop system that automatically tracks blood sugar levels and delivers insulin as necessary. The system is being heralded as a major advance in treating diabetes, because it significantly reduces the need for finger sticks and insulin shots. Will this new device be a hit?

There are about 1.25 million Americans with Type 1 diabetes, and for these patients, managing their blood sugar levels can seem like a full-time job.

Image source: Getty Images.

Type 1 diabetes patients must regularly check their blood sugar levels with finger sticks, and then dose themselves with insulin when blood sugar levels require it. Unfortunately, this scattershot approach to managing the disease results in many patients failing to maintain appropriate blood glucose levels, especially at night, or when exercising. Because time spent outside of desired blood sugar ranges can accelerate disease progression and lead to life-threatening conditions, inadequately controlled diabetes remains a big problem.

Fortunately, medical device makers have developed new technology like insulin pumps and continuous glucose monitors that help patients better control their disease, however, until now, there wasn't a FDA-approved closed-loop system for the monitoring and dosing of insulin available.

The FDA gave Medtronics MiniMed 670G a green light after trial results showed that it helped patients remain within their desired blood sugar range over a three-month period. The trial included bothadults and children with Type 1 diabetes, and A1C levels fell from 7.7% to 7.1% in children and from 7.3% to 6.8% in adults. There also was a 44% decline in time spent with blood glucose below 70 mg/dL and a 40% decline in time spent with dangerous hypoglycemia, or levels below 50 mg/dL.

Image source: Medtronic.

The MiniMed 670G uses sensors to automatically monitor blood glucose levels every five minutes and it uses a pump to automatically administer insulin as it's needed. A daily finger-stick is still required to calibrate the system, and the insulin pump needs to be refilled every few days, but the system still significantly reduces the treatment burden on patients.

The MiniMed 670G system includes a sensor that's attached to the body and that must be changed weekly, an insulin pump that's worn on the waist, and an infusion patch that connects to the pump to administer insulin via a catheter.

Medtronic's device is an important advance in automating diabetes treatment, but it's not approved for use in Type 1 diabetes patients who are younger than 14 (yet), it still requires some patient involvement, and it's arguably a bit bulkier of a solution for active patients, who may prefer wireless pumps, such as Insulet's (NASDAQ:PODD) Omnipod.

Omnipod is atubeless insulin management system that delivers insulin for up to three days using a wireless programming device. Oftentimes, patients pair Omnipod up with a continuous glucose monitor, such as those made byDexCom(NASDAQ:DXCM), to provide even better control of their disease.

Medtronic only began shipping the MiniMed 670G to patients recently, so the verdict isn't in on whether it will win away consumers from these other solutions. If it does, then it could be an important new source of revenue for Medtronic. However, that tailwind could only be temporary, because the MiniMed 670G may face stiff competition soon.Insulet, for example, is working on its own closed-loop system that incorporates DexCom's sensors, and if trials are successful, its system could be available as soon as next year. Similar systems are also being developed by Tandem and Bigfoot Biomedical, so you'll want to pay attention to their progress, too.

Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.

Follow this link:
Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes? - Motley Fool

Posted in Diabetes | Comments Off on Is Medtronic’s Artificial Pancreas the Next Big Thing in Diabetes? – Motley Fool

HEALTH MATTERS: Busting Diabetes Myths – Packet Online

Posted: April 13, 2017 at 7:40 pm

A diagnosis of diabetes can be scary and confusing for many people, especially with all the myths surrounding the disease and how to manage it.

But if you are one of the millions of Americans diagnosed with diabetes or pre-diabetes each year, understanding the facts can help you make positive changes and gain control over the condition so you can lead a healthier life.

The Diabetes Management Program at University Medical Center of Princeton (UMCP) helps adults and children diagnosed with diabetes learn how to live with the condition. It also provides education to enable patients to make informed lifestyle changes based on facts rather than myths.

MYTH:The most important item to watch in your diet is sugar, and if a food is sugar-free, you can eat as much as you want.

FACT:Years ago, people were advised that to prevent and control diabetes they just needed to avoid or reduce sugar in their diet. However, just because a food is low in sugar or sugar-free, it could still be high in carbohydrates. And total carbohydrates are the real culprits in raising glucose levels after you eat.

Carbohydrates include starches (such as rice, pasta, bread, potatoes, and cereals), fruits, milk and vegetables. Most vegetables are low in carbohydrates, and protein and fats have minimal or no carbohydrate. When it comes to managing diabetes, it is not enough to just avoid sugar, it is important to watch your total carbohydrate intake for meals and snacks.

Everyone is different though and the amount of carbohydrates you need varies by individual. For example, people with type 2 or pre-diabetes may need to limit or controlthe amount of carbs they eat each day, while someone with type 1 diabetes may need to match their insulin doses to how much carbohydrate they want to eat.

MYTH:You dont need to do anything if you are told you have pre-diabetes or borderline diabetes.

FACT:Not true! Pre-diabetes is defined as having fasting glucose levels between 100-125, or a hemoglobin A1c between 5.7-6.4. This is higher than normal, but right below the cut-off point for diabetes. More than 86 million American adults more than 1 out of 3 have pre-diabetes, according to the Centers for Disease Control and Prevention.

While having pre-diabetes is a risk factor for developing diabetes, you may be able to reverse the progression or delay the development for years through diet and exercise. If you are able to lose 5 to 10 percent of your weight and get at least 150 minutes of physical activity each week, you can increase your chances of keeping diabetes at bay. In addition, if you are diagnosed with pre-diabetes, it is important to follow up with your doctor and have your hemoglobin a1c levels checked every three months, and to monitor your glucose at home if necessary or desired.

MYTH:There is only one diabetic diet, or one way to eat for managing diabetes.

FACT:Also, not true! There may be general guidelines to make it easier to get started, but each person needs an individualized plan, taking into consideration their preferences, lifestyle, activity, weight, diabetes medications, and glucose levels. While one person may be able to eat three regular meals a day, another may benefit from eating three small meals and two to three snacks. Amounts of carbohydrates, fat, and calories will be different for each person as well. For someone monitoring their glucose levels at home, they can see the effects of their diet on their glucose levels and make changes accordingly. Registered dietitians, especially those who are also certified diabetes educators, can help develop a diet plan tailored to individual needs.

MYTH:If you cant exercise for 30 to 60 minutes or more a day, dont bother.

FACT:Research has shown that just 10 to 15 minute increments of exercise or activity two to three times daily or even every other day can be beneficial and reduce glucose levels, especially after meals. For people who sit most of the day, getting up and walking around for 5 minutes every 30 to 60 minutes can be beneficial as well. Also, exercise can include chair exercises, strength training and using weights, or a combination of aerobic and strength. Put simply, moving more is good for your health.

Nationally Recognized Care

There is now a wide range of effective treatments for diabetes, greatly reducing the risks of serious complications. Finding a healthy personal balance learning to control your blood sugar levels through a combination of good nutrition, exercise and often medication is key to successfully managing your diabetes.

The Diabetes Management Program at UMCP is recognized by the American Diabetes Association as a quality diabetes self-management education program that meets the National Standards for Diabetes Self-Management Education. This award is based on a rigorous clinical review process every four years to ensure high standards of diabetes care and education.

The program is staffed by a multidisciplinary team of diabetes specialists, including registered nurses and registered dietitians, who work closely with each individual patient and their physician and other healthcare providers to help effectively manage their diabetes and enjoy an improved quality of life. Services include:

Individual and group education sessions by registered nurses and dietitians

Blood glucose monitoring instruction

Community outreach programs

Diabetes care and management for pre-pregnancy/conception and during pregnancy

Medical Nutrition Therapy/nutrition education and meal planning

Professionally facilitated monthly support groups

For more information about the Diabetes Management Program at UMCP, go to http://www.princetonhcs.org or call 609-853-7890.

Sandra Byer-Lubin is a registered dietitian and certified diabetes educator with University Medical Center at Princetons Diabetes Management Program.

See more here:
HEALTH MATTERS: Busting Diabetes Myths - Packet Online

Posted in Diabetes | Comments Off on HEALTH MATTERS: Busting Diabetes Myths – Packet Online

Happening Today: United, ‘Cocaine Cowboy,’ Diabetes, Charlie Murphy – NBC New York

Posted: April 13, 2017 at 7:40 pm

What to Know

Get the top headlines of the day in your morning briefing from NBC 4 New York, Monday through Friday. Sign up for our newsletterhere.

United to Reimburse Passengers on Flight Man Was Dragged From

United Airlines sought to quell the uproar over a man being dragged off a plane by announcing it would no longer ask police to remove passengers from full flights and would compensate customers who were on the flight when the man was removed. In an interview with ABC's "Good Morning America" aired, United parent company CEO Oscar Munoz said he felt "ashamed" watching video of the man being forced off the jet. He has promised to review the airline's passenger-removal policy. Munoz, who leads United's parent company, apologized again to Kentucky physician David Dao, his family and the other passengers who witnessed him being taken off the flight. In an effort to calm the backlash, United also announced that passengers on United Express Flight 3411 would be compensated equal to the cost of their tickets.

'Cocaine Cowboy' Arrested After 26 Years on the Run, Officials Say

One of the original 'Cocaine Cowboys' was arrested after 26 years on the run. Gustavo Falcon, who also goes by several aliases, including Augusto Falcon and "Taby," was finally captured by a team of U.S. Marshals from Miami working with U.S. Marshals in the Orlando-Kissimme area. The team focused specifically on the address of a rental property in Kissimmee, and while conducting surveillance, they saw what they thought was Falcon and his wife exit the house to go on a bike ride. When agents stopped Falcon, he had fake driver's licenses dating back to 1997, using Miami addresses, federal officials said. The 55-year-old also had fake licenses for his wife, as well as his children, who are now in their 30s, according to U.S. Marshals. Falcon did not resist the arrest and even confessed to his real identity, officials said. He was booked into the Osceola County Jail and will make his first federal court appearance Thursday.

Officer Charged With Shooting Autistic Man's Caretaker, Authorities Say

A North Miami police officer who shot the unarmed caretaker of an autistic man has been charged with attempted manslaughter, the Miami-Dade State Attorney's Office announced. Officer Jonathan Aledda also was charged with misdemeanor culpable negligence in the shooting of behavioral therapist Charles Kinsey. Aledda, a four-year veteran of the department, was arrested and was later released from Miami-Dade Turner Guilford Knight Correctional Center on $6,000 bond. The criminal charges come after what officials said was a lengthy investigation by the State Attorney's Office and Florida Department of Law Enforcement into the July 2016 shooting. Kinsey, a caretaker at a home for people with mental disabilities, was lying on the ground, with his hands up in the air, next to his adult patient when he was shot in the leg by Aledda on July 18. Cellphone video captured events leading up to the shooting.

Apple Has Secret Team Working on the Holy Grail for Treating Diabetes

Apple has hired a small team of biomedical engineers to work at a nondescript office in Palo Alto, miles from corporate headquarters, CNBC reported. They are part of a super secret initiative, initially envisioned by the late Apple co-founder Steve Jobs, to develop sensors that can non-invasively and continuously monitor blood sugar levels to better treat diabetes, according to three people familiar with the matter. Such a breakthrough would be a "holy grail" for life sciences. Many life sciences companies have tried and failed, as it's highly challenging to track glucose levels accurately without piercing the skin. The initiative is far enough along that Apple has been conducting feasibility trials at clinical sites across the Bay Area and has hired consultants to help it figure out the regulatory pathways, the people said.

Trans Fat Ban Linked With Fewer Heart Attacks & Strokes, Study Shows

Local bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties, a new study suggests. The study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say. The U.S. Food and Drug Administration in 2015 gave the food industry until next year to eliminate artificial trans fats from American products. New York City enacted a restaurant ban on the fats in 2007 and several counties in the state did the same. Hospital admissions for heart attacks and strokes in those areas declined 6 percent starting three years after the bans, compared with counties without bans.

Comedian Charlie Murphy Dies at 57, His Publicist Says

Comedian and actor Charlie Murphy, who stepped out of his brother Eddie's shadow as a talent in his own right, has died at 57, according to his publicist. Murphy died of leukemia, publicist Domenick Nati told NBC Los Angeles. Fellow comedian Chris Rock posted a picture of Murphy on Twitter with a message of mourning: "We just lost one of the funniest most real brothers of all time. Charlie Murphy RIP." Murphy was perhaps best known as an ensemble actor in the comedy "Chappelle's Show," where he told belief-defying stories about spending time with Rick James and Prince. In the recurring segment "Charlie Murphy's True Hollywood Stories," Murphy would recount how his brother's fame brought him into the orbit of the biggest stars. His versions of the experiences, played out by him, Chappelle and others, became enduring hits. He was born in New York City.

Josh Brolin Set to Play Cable in 'Deadpool 2,' Representatives Say

Josh Brolin is expanding his comic book movie repertoire. Representatives for the actor said Brolin has been set to play the part of Cable in 20th Century Fox's "Deadpool 2" opposite lead Ryan Reynolds. Brolin also plays the supervillain Thanos in various "Avengers" movies for competing studio Disney. Michael Shannon had been widely rumored to be the top pick for the Deadpool co-star. "Deadpool" became a breakout hit in 2016, grossing over $783 million worldwide. The irreverent and very R-rated comic book film even became an unlikely awards contender late in the game with two Golden Globe nominations and a Directors Guild of America Award nomination for Tim Miller.

Published at 6:52 AM EDT on Apr 13, 2017

See the original post:
Happening Today: United, 'Cocaine Cowboy,' Diabetes, Charlie Murphy - NBC New York

Posted in Diabetes | Comments Off on Happening Today: United, ‘Cocaine Cowboy,’ Diabetes, Charlie Murphy – NBC New York

Gut bacteria compound may help to prevent type 2 diabetes – Medical News Today

Posted: April 13, 2017 at 7:40 pm

New research from Finland suggests that higher blood levels of indolepropionic acid - a product of gut bacteria that is increased by a fiber-rich diet - may help to protect against type 2 diabetes.

Writing about the discovery in the journal Scientific Reports, the team - led by researchers from the University of Eastern Finland in Kuopio - suggests that it increases our understanding of the important part played by gut bacteria in the relationship between diet, metabolism, and health.

Diabetes is a disease in which the blood contains too much sugar, or glucose - a vital source of energy for the body's cells.

If uncontrolled, high blood sugar can lead to blindness, kidney failure, heart disease, stroke, and amputation of lower limbs.

Levels of blood sugar are regulated by the hormone insulin, which is made in the pancreas.

The type of diabetes that develops depends on whether the high blood glucose results from lack of insulin (type 1 diabetes) or the body's inability to use insulin (type 2 diabetes).

Type 2 diabetes is by far the most common form of diabetes around the world and largely develops from being overweight and not exercising.

Once a disease occurring only in adults, the number of children with type 2 diabetes is now on the rise.

Fast facts about diabetes

Learn more about diabetes

The global prevalence of diabetes among adults (90 percent of which is type 2 diabetes) has gone up from 4.7 percent in 1980 to 8.5 percent in 2014.

In the United States, there are more than 29 million people living with diabetes. There are also 86 million living with prediabetes, a serious condition that raises the risk of developing type 2 diabetes and other lifelong health problems.

In their study introduction, the researchers note that it is now well-known that factors such as genes, lifestyle, and diet can influence the risk of developing type 2 diabetes.

However, what is less clear is what happens at the molecular level to link these factors to the disease.

The new study uses metabolomics, a relatively new technology that allows scientists to quickly assess the metabolite profiles of people.

Metabolites are molecules that cells in the body - including gut bacteria - produce as byproducts of their activity.

Using a particular tool called "nontargeted metabolomics analysis," the researchers assessed the metabolite profiles of 200 participants in the Finnish Diabetes Prevention Study who had impaired glucose tolerance and were overweight when the study began.

The participants fell into two groups. One group developed type 2 diabetes within 5 years, and the other group did not develop type 2 diabetes during the 15 years of follow-up.

When the researchers compared the metabolite profiles of the two groups, they found that what stood out was differences in levels of indolepropionic acid and certain lipid metabolites.

Further analysis suggested that having high blood levels of indolepropionic acid, a byproduct of gut bacteria, appeared to protect against developing type 2 diabetes.

Also, a diet rich in fiber and whole grain foods appears to increase levels of indolepropionic acid, which in turn raises the amount of insulin produced by the beta cells in the pancreas, note the authors.

The team confirmed the findings by looking at the link between indolepropionic acid and risk for type 2 diabetes in the data from two other studies: the Finnish Metabolic Syndrome In Men Study, and the Swedish Vsterbotten Intervention Project. These also showed that indolepropionic acid appears to protect against type 2 diabetes.

The researchers suggest that their study shows that it may be more feasible to use metabolite profiles rather than identifying the bacteria themselves (which is a more complex process) to look at links with diseases such as diabetes.

"Earlier studies, too, have linked intestinal bacteria with the risk of disease in overweight people. Our findings suggest that indolepropionic acid may be one factor that mediates the protective effect of diet and intestinal bacteria."

Corresponding author Dr. Kati Hanhineva

Learn how statins are linked to a higher risk of diabetes in older women.

View post:
Gut bacteria compound may help to prevent type 2 diabetes - Medical News Today

Posted in Diabetes | Comments Off on Gut bacteria compound may help to prevent type 2 diabetes – Medical News Today

Diabetes awareness, treatment need big push among minorities – Chicago Sun-Times

Posted: April 13, 2017 at 7:40 pm


Chicago Sun-Times
Diabetes awareness, treatment need big push among minorities
Chicago Sun-Times
Nearly four of every 10 people in parts of Chicago's South and West Side neighborhoods have Type 2 diabetes, risking serious and even life-threatening health problems as they age. Rates of diabetes range from 17 percent to 37 percent in Chicago's South ...

Originally posted here:
Diabetes awareness, treatment need big push among minorities - Chicago Sun-Times

Posted in Diabetes | Comments Off on Diabetes awareness, treatment need big push among minorities – Chicago Sun-Times

Patients with Diabetes Recognized at Deaconess Hospital Campus – Tristatehomepage.com

Posted: April 13, 2017 at 7:40 pm

Logo provided bywww.journeyawards.com

Logo provided bywww.journeyawards.com

Twenty-five patients with type 1 diabetes will be recognized with a 'Lilly Diabetes Journey Award,' during a celebration on the Deaconess Hospital campus on Thursday.

During the celebration, a patient will share his personal story during the event, and Deaconess Clinic endocrinologists will also participate in the program.

Six individuals will be recognized for 50 years of successfully managing their type 1 diabetes.

The Journey Awards ceremony will celebrate the significant journey people have taken to manage their type 1 diabetes with the help of insulin.

With friends, family, physicians, and others in attendance, recipients will be presented with a custom-engraved medal, along with a congratulatory letter signed by Lilly's President and Chief Executive Officer. The Lilly Diabetes Journey Awards program was established by Eli Lilly, grandson of Lilly's founder, Col. Eli Lilly, in 1975 to recognize individuals who have successfully managed their diabetes with the help of insulin for 10, 25, 50, or 75 years or more.

These local Journey Awards recipients will join the thousands of individuals who have received the honor since the award was first established. The celebration begins at 4:30 in Johnson Hall, which is located in the Health Sciences Building on Edgar Street on the Deaconess Hospital campus.

Read the original:
Patients with Diabetes Recognized at Deaconess Hospital Campus - Tristatehomepage.com

Posted in Diabetes | Comments Off on Patients with Diabetes Recognized at Deaconess Hospital Campus – Tristatehomepage.com

Three universities research spinach to bioengineer cell tissues – Indiana Gazette

Posted: April 12, 2017 at 7:45 am

JOBESBORO, Ark. Popeye isnt the only one reaping the benefits of spinach. Arkansas State University researcher Fabricio Medina-Bolivar said spinach might also be used in the future to repair damaged hearts.

The use of spinach to bioengineer human cell tissues is the result of work between scientists at three universities to study human tissue regeneration to treat diseases or traumatic injuries.

It began when researchers at Worcester Polytechnic Institute, attempting to reproduce human tissues, particularly heart tissues, had trouble creating a vascular system to deliver blood deep into developing tissue.

They finally turned to nature to find a solution and asked Arkansas State researchers at the Arkansas Biosciences Institute for help.

The Jonesboro scientists, known for their plant research, joined the team roughly two years ago.

Taking an interdisciplinary approach, researchers from Arkansas State, WPI and the University of Wisconsin-Madison began discussing whether they could use plants as a scaffold, or platform, to create blood vessels.

WPI has a way to remove the cells from human tissues. Why dont we take that approach and use that in plants? Medina-Bolivar said. It worked. So, we were able to remove everything that was inside the roots, or the cells, and then what remains is a scaffold or surface that can be seeded with human cells.

The beauty of the system is that we can re-create now using the veins that exist in the leaf or the remineralization that you see, for example, in the roots so we can use this as a potential blood vessel that can then be planted in a heart that has been damaged.

Joshua Gershlak, a WPI graduate student, developed the process for removing plant cells from spinach leaves by streaming a detergent solution through the leaves veins.

I had done decellularization work on human hearts before, Gershlak said in a news release, and when I looked at the spinach leaf its stem reminded me of an aorta. So I thought, lets perfuse right through the stem. We werent sure it would work, but it turned out to be pretty easy and replicable.

The scaffold is a framework made primarily of cellulose, a natural substance that is not harmful to people and has already been used in a wide variety of regenerative medicine applications.

The team has since also successfully removed cells from parsley, sweet wormwood and peanut hairy roots. The technique is hoped to work with other plant species that could be adapted for specialized tissue regeneration studies.

For example, the spinach leaf might be better suited for cardiac tissue, while the jewelweed may be better suited for an arterial graft and the vascular columns of wood for use in bone engineering, according to a paper published on the teams initial findings.

Medina-Bolivar said these systems could be used to make a patch out of either the leaves or the roots to repair areas of a heart damaged by a heart attack.

By exploiting the benign chemistry of plant tissue scaffolds, the researchers wrote in their paper, we could address the many limitations and high costs of synthetic, complex composite materials. Plants can be easily grown using good agricultural practices and under controlled environments.

That actually happening is still years away; more work is needed. Medina-Bolivar said they need to find what root systems are most amenable and to study additional ways the systems could be used.

At WPI, Glenn Gaudette, a professor of biomedical engineering, said in a news release that studies continue for ways to optimize the decellularization process and further characterize how various human cell types grow while they are attached to and are potentially nourished by plant-based scaffolds.

They are also looking at engineering a secondary vascular network for the outflow of blood and fluids from human tissue.

The continuation of this type of research will take several million dollars with the team working off grants and continuously looking for new funding opportunities.

We have a lot more work to do, but so far this is very promising, Gaudette said. Adapting abundant plants that farmers have been cultivating for thousands of years for use in tissue engineering could solve a host of problems limiting the field.

Medina-Bolivar admits he has already started receiving emails from people who never thought it was possible. He said the beauty of looking in nature for answers is that nature has all types of plants that can be used for different kinds of applications.

See the original post here:
Three universities research spinach to bioengineer cell tissues - Indiana Gazette

Posted in Arkansas Stem Cells | Comments Off on Three universities research spinach to bioengineer cell tissues – Indiana Gazette

Biotechnology: navigating a minefield – Youris.com

Posted: April 12, 2017 at 7:44 am

In our fast-moving world, biotech is at the forefront of developments but, by its very nature, it can provoke ethical and moral concerns.

The European Patent Office (EPO) has faced opposition in the past, for instance, over patents relating to processes for re-engineering genes, for use in medical research into cancer treatment. These processes could apply to various animals, including great apes and that became a magnet for criticism from animal rights campaigners.

The number of patent filings for biotechnology increased by 0.3 percent in 2016, to 5,744 making it the tenth largest sector in its field.

Youris.com spoke to Benoit Battistelli, President of the EPO, about the role of patent protection and how it can aid biotechnology innovation and the wider bioeconomy despite the obstacles faced by some.

Benoit Battistelli -Courtesy of EPO

How much of a focus is the bioeconomy for patents and what are some of the key developments? Biosciences play an important role in patent applications at the EPO, given the growing convergence of technologies, which is widely responsible for technical progress in a wide number of sectors. Such inventions are mainly found in industrial biotechnology, for instance, in the development of novel products such as new detergents, functional food or even new eco-friendly material in construction, such as pollution-eating concrete and self-healing concrete.

The area of clean energy production is also very important. For example, when it comes to using biomass as an energy source [editors note: In 2011, a Danish inventor won a European Inventor Award organised by the EPO for developing a system which increases the types of biomass fuels that can be used. Typically, biomass materials have to be dried before they can be used as fuel, but Jens Dall Bentzens furnace design can also burn materials with a moisture content of up to 60 percent. Hes since reported to have attracted interest from Europe and the US, selling the furnace to an American manufacturer, as well as building two others for use in Denmark].

Is the bioeconomy an increasing sector? Biotech is among our top ten technical fields and it has increased. At the end of the patent granting process, its about 50 percent on average that become a patent. Its only 26 or 27 percent in the case of biotech. Why? Because it is a very sensitive issue and we are applying the patentability criteria very rigorously. There are huge European capacities in biotech and we have seen that we must find a good balance between the regulatory constraints and the economic capacities that this sector represents.

The position of the EPO is very clear and simple. There is an EU directive concerning biotech, which we respect and which we have integrated in our own legal framework, the European Patent Convention. Then you have the interpretations of the Directive by the European Court of Justice and we adapt our practice to these judgements.

Overall, how complicated is it to obtain a patent, and is it expensive? I would not say that it is complicated, but it is a difficult process, because we always start from the basis thata patent is an exception to the principle of free trade, free industry, free competition. Globally, for around20 to 25,000 euros, you can obtain a patent as the EPO. For this amount, 5,000 euros are the EPO fees and the rest is the fees of those who helped to draft a patent and then discuss it with the patent office.

So, with a patent, you are giving the holderthe exclusive right of commercially exploiting his invention, for a certain period of time, amaximum 20 years.

This article is part of the communication of theProBIO project, a support action for KBBE projects which identifies research results to facilitate their uptake into the relevant sector.

youris.com provides its content to all media free of charge. We would appreciate if you could acknowledge youris.com as the source of the content.

See the rest here:
Biotechnology: navigating a minefield - Youris.com

Posted in Biotechnology | Comments Off on Biotechnology: navigating a minefield – Youris.com

Technical Roundup On Two Stocks – Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO) – Post Analyst

Posted: April 12, 2017 at 7:44 am

Technical Roundup On Two Stocks - Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO)
Post Analyst
Puma Biotechnology, Inc. has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 27.36% of shares outstanding. The stock sank -19.31% last month and is up 17.75 this year. Wall ...

and more »

Continued here:
Technical Roundup On Two Stocks - Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO) - Post Analyst

Posted in Biotechnology | Comments Off on Technical Roundup On Two Stocks – Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO) – Post Analyst

Venture capitalists are betting big on regenerative medicine, but it’s … – Quartz

Posted: April 12, 2017 at 7:43 am

Until the myth of the fountain of youth proves true, regenerative medicine is the best hope weve got for fixing failed body parts and, as a result, living longer. Scientists wont be able to bottle forever. They are, however, working on engineering human cells, tissues, and organs that can repair themselves.

Basically, theyre trying to heal body parts using cells or tissue grown from stem cells, and by prompting regeneration with biologically active drugs that would essentially restart parts by forcing new growth, among other approaches. But its still a speculative venture, say Goldman Sachs analysts in an April 4 report on venture capital going into this novel frontier.

Perfecting processes for regenerating body parts is no mean feat, technically speaking. Plus, there are ethical questions to resolve and regulatory hurdles to overcome. In other words, itll take a while before new parts are available.

Nonetheless, investors are interested in the field, and especially in companies working with stem cells. Goldman analysts believe regenerative medicine is attractive because of its vast potential to eventually cure common and rare diseases in almost any tissue or organ, including the heart, liver, and lungs.

So, moneys going to regenerative medicine, at a rate of hundreds of millions of dollars annually. In 2010, the field attracted about $200 million in venture capital and in 2016, that figure had quadrupled. Stem cell technology attracts the vast majority of investment; $700 million of the $800 million dedicated to regenerative medicine in 2016 went to stem cell projects.

But analysts noted that the number of deals hasnt increased accordingly. Between 2010 and 2016 deals remained in a range of 30 to 40 while investment rose pretty steadily. This suggests that a few companies attracted larger investments per deal over time from venture capital firms.

Companies partnered with science giantslike BlueRock Therapeutics, which works with stem cell pioneer and Nobel laureate Shinya Yamanaka of Kyoto Universityget the largest investments and valuations, according to Goldman Sachs.

Analysts also remarked on Unity Biotechnology, which is developing a technique to eliminate senescent cellsor expiring cellsto increase longevity and maintain youthfulness, and has been shown to work in mice. Senescence is like a biological emergency brake cells use to stop dividing and multiplying out of control. But after the brakes been pulled, the senescent cells remain and accumulate, secreting inflammatory molecules that harm neighboring cells and tissues. Selectively removing them could keep people younger, healthier longer, according to the company.

Scientists seek funding from public sources too, of course. At the University of Washingtons Institute for Stem Cell and Regenerative Medicine, for example, researchers are manipulating stem cells to heal and restore the function in hearts, eyes, kidneys and other tissues, according to Charles Murray, the institutes interim director. In an April 9 editorial in the Seattle Times, he writes, This year, we also seek a first-time investment from our state legislature.

Continued here:
Venture capitalists are betting big on regenerative medicine, but it's ... - Quartz

Posted in Cell Medicine | Comments Off on Venture capitalists are betting big on regenerative medicine, but it’s … – Quartz

Page 1,604«..1020..1,6031,6041,6051,606..1,6101,620..»